QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NBIX

QT83Neurocrine Biosciences, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
158.29
-0.71-0.45%
OverviewShort InterestFilings
NBIXQT83Neurocrine Biosciences, Inc.·NASDAQ
OverviewShort InterestFilings
158.29-0.45%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E23.90EPS (ttm)
6.49
Insider Own1.80%
Shs Outstand100.55M
Perf Week-2.72%
Market Cap15.99BForward P/E16.61EPS next Y9.53Insider Trans0.49%Shs Float-Perf Month2.55%
Enterprise Value16.13BPEG0.20EPS next Q2.11Inst Own-Short Float-Perf Quarter22.04%
Income668.28MP/S5.15EPS this Y17.57%Inst Trans-Short Ratio-Perf Half Y6.42%
Sales3.10BP/B4.69EPS next Y24.89%ROA13.63%Short Interest-Perf YTD11.61%
Book/sh33.88P/C18.50EPS next 5Y18.20%ROE21.64%52W High169.57 -6.65%Perf Year26.75%
Cash/sh13.09P/FCF19.23EPS past 3/5Y-ROIC13.68%52W Low122.14 29.60%Perf 3Y-
Dividend Est.-EV/EBITDA16.87Sales past 3/5Y24.32% 22.29%Gross Margin98.17%Volatility1.86% 1.91%Perf 5Y-
Dividend TTM-EV/Sales5.20EPS Y/Y TTM110.33%Oper. Margin25.19%ATR (14)4.86Perf 10Y-
Dividend Ex-Date-Quick Ratio2.85Sales Y/Y TTM31.80%Profit Margin21.55%RSI (14)52.81Recom2.14
Dividend Gr. 3/5Y-Current Ratio2.93EPS Q/Q2325.00%SMA20-0.93%Beta0.76Target Price186.31
Payout0.00%Debt/Eq0.12Sales Q/Q42.23%SMA507.28%Rel Volume2.22Prev Close159.00
Employees1,800LT Debt/Eq0.13EarningsJul 29SMA20012.04%Avg Volume1.22MPrice158.29
IPO DateMay 23, 1996Option/ShortYes / YesEPS/Sales Surpr.59.02% 6.12%Net Debt/EBITDA0.15Volume2,711,978Change-0.45%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26ResumedGoldman SachsBuy$213
May-21-26InitiatedBernsteinOutperform$221
May-06-26ReiteratedOppenheimerOutperform$220 → $230
May-06-26ReiteratedPiper SandlerOverweight$179 → $207
Apr-06-26ReiteratedOppenheimerOutperform$192 → $220
Mar-10-26ReiteratedCantor FitzgeraldOverweight$123 → $195
Feb-23-26InitiatedWolfe ResearchOutperform$160
Feb-17-26ReiteratedTruist Financial$169 → $140
Feb-12-26ReiteratedMorgan StanleyEqual Weight$175 → $173
Feb-12-26ReiteratedH.C. Wainwright$198 → $192
Latest News
Jun-16-26
Jun-16-2610:40AM
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout CandidateChartMill
Jun-15-26
Jun-15-2608:10PM
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal PeriodYahoo
08:05PM
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026Yahoo
04:15PM
Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWSBenzinga
02:55PM
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?Yahoo
12:35PM
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026Yahoo
12:30PM
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026Yahoo
08:36AM
Neurocrine Biosciences Presents New Two-Year Data From Phase 3 CAHtalyst Pediatric Trial Of CRENESSITY At Endocrine Society's Annual MeetingBenzinga
Jun-10-26
Jun-10-2604:44PM
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New BuysBenzinga
04:44PM
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New BuysBenzinga
12:10PM
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book StrategyChartMill
12:10PM
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book StrategyChartMill
Jun-09-26
Jun-09-2603:52PM
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Jun-08-26
Jun-08-2608:05PM
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of PatientsYahoo
12:30PM
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental DisabilitiesYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,1042,8612,355
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A575234
Gross Profit3,0462,8082,321
Selling, General and Administrative Excl. Other1,1991,1561,007
Research and Development1,0481,016731
Other Operating Expense181713
Operating Income782619571
Interest Expense00127
Unusual Expense
———
Non-Operating Income (Expense)-145-17-42
Net Income Before Taxes938705486
Income Taxes269227145
Consolidated Net Income670479341
Net Income From Continuing Operations670479341
Net Income670479341
EPS (Recurring)6.714.813.40
EPS (Basic, Before Extraordinaries)6.714.813.40
EPS (Diluted)6.494.673.29
EBITDA956667640
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio24.3930.37—
Price To Sales Ratio5.154.96—
Gross Margin98.1398.1598.56
Operating Margin25.1921.6424.25
Net Margin21.5916.7414.48
Shares Outstanding101100100
Market Capitalization15,98714,183—
Operating Lease Expense
———
Insider Trading Volume
$165.48$152.54$139.61$126.67$113.74● Close Price0.00M10.86M21.73M32.59M43.45MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SHERWIN STEPHEN ADirectorJun 05 '26Option Exercise64.1050,0003,205,00040,860Jun 09 12:00 AM
SHERWIN STEPHEN ADirectorJun 05 '26Sale165.3225,0004,132,96915,860Jun 09 12:00 AM
Norwalk Leslie VDirectorJun 04 '26Sale168.061,250210,0722,838Jun 08 12:00 AM
Keswani Sanjay ChandruChief Medical OfficerJun 02 '26Option Exercise0.006,42409,634Jun 04 12:00 AM
Cooke JulieChief Human Resources OfficerJun 02 '26Option Exercise81.4949,9304,068,79659,311Jun 04 12:00 AM
Cooke JulieChief Human Resources OfficerJun 02 '26Sale156.2236,9375,770,23522,374Jun 04 12:00 AM
Onyia JudeChief Scientific OfficerJun 01 '26Sale160.2511,0001,762,71025,846Jun 02 12:00 AM
Onyia JudeChief Scientific OfficerJun 01 '26Option Exercise84.7422,0001,864,28036,846Jun 02 12:00 AM
Delaet IngridChief Regulatory OfficerMay 29 '26Sale156.712,261354,32116,225Jun 02 12:00 AM
Delaet IngridChief Regulatory OfficerMay 29 '26Option Exercise79.024,522357,32818,486Jun 02 12:00 AM
Onyia JudeChief Scientific OfficerMay 27 '26Option Exercise84.7422,0001,864,28036,846May 29 12:00 AM
Onyia JudeChief Scientific OfficerMay 27 '26Sale155.5311,0001,710,86525,846May 29 12:00 AM
Boyer David W.Chief Corp. Affairs OfficerMay 26 '26Sale156.643,888609,0237,799May 28 12:00 AM
SHERWIN STEPHEN ADirectorMay 21 '26Option Exercise0.006,636015,860May 21 12:00 AM
Sharp ShaliniDirectorMay 21 '26Option Exercise0.003,31804,088May 21 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR